Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc.

赛诺菲宣布完成其对Vigil Neuroscience, Inc.的收购

(“Vigil”). This acquisition strengthens Sanofi’s early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer’s disease. In addition, the acquisition of Vigil’s preclinical pipeline will further strengthen Sanofi’s research in various neurodegenerative diseases..

（“Vigil”）。此次收购通过VG-3927加强了赛诺菲在神经病学领域的早期研发管线，VG-3927是一种新型的口服小分子TREM2激动剂，将在阿尔茨海默病患者的二期临床研究中进行评估。此外，收购Vigil的临床前管线将进一步加强赛诺菲在各类神经退行性疾病方面的研究。

In June 2024, Sanofi made a $40 million strategic investment in Vigil that included the exclusive right of first negotiation for an exclusive license, grant, or transfer of rights to research, develop, manufacture, and commercialize VG-3927.

2024年6月，赛诺菲对Vigil进行了4000万美元的战略投资，其中包括获得对VG-3927进行研究、开发、制造和商业化的独家许可、授予或转让权利的优先谈判权。

Under the terms of the acquisition agreement, Sanofi and Vigil have agreed to the following:

根据收购协议的条款，赛诺菲和Vigil已同意以下内容：

Sanofi acquired all outstanding common shares of Vigil for $8 per share in cash at closing, representing an equity value of approximately $470 million (on a fully diluted basis)

赛诺菲在收盘时以每股8美元的现金收购了Vigil所有已发行的普通股，股权价值约为4.7亿美元（按完全稀释计算）。

In addition, Vigil’s shareholders received a non-transferrable contingent value right (CVR) per Vigil share, which entitles its holder to receive a deferred cash payment of $2, conditioned upon the first commercial sale of VG-3927.

此外，Vigil 的股东每股 Vigil 股份获得了不可转让的或有价值权 (CVR)，该权利赋予其持有人在 VG-3927 首次商业销售时获得 2 美元的递延现金付款的权利。

VGL101, Vigil’s second clinical program, was not acquired by Sanofi. As previously communicated, the acquisition of Vigil is not expected to impact Sanofi's financial guidance for 2025.

VGL101，Vigil的第二个临床项目，并未被赛诺菲收购。正如之前所传达的，对Vigil的收购预计不会影响赛诺菲2025年的财务指导。

About Sanofi

关于赛诺菲

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time..

赛诺菲是一家以研发为驱动、以人工智能为助力的生物制药公司，致力于改善人们的生活并实现令人瞩目的增长。我们凭借对免疫系统的深刻理解，发明能够治疗和保护全球数百万人的药物和疫苗，同时拥有一条创新的研发管线，有望惠及数百万人。我们的团队秉承一个使命：追逐科学奇迹以改善人们的生活；这激励我们推动进步，并通过应对当今最紧迫的医疗、环境和社会挑战，为我们服务的人民和社区带来积极影响。

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

赛诺菲在 EURONEXT（欧洲证券交易所）上市，股票代码为 SAN；同时在 NASDAQ（纳斯达克）上市，股票代码为 SNY。